A clinical study of LCOX to check its efficacy and tolerability in osteoarthritis patients of Knee.

A randomized Double blind placebo controlled trial to check Efficacy and tolerability of LCOX- an herbal formulation in osteoarthritis of Knee.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/06/005864

Enrollment

100

Registered

2015-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- osteoarthritis of knee joints

Interventions

Intervention1: Tablet LCOX: LCOX contains: Boswellia Serrata 300 mgs Withania Somnifera 100 mgs Cissus quadrangularis 100 mg Dosage: 2 tablets twice a day. Route of administration: oral Duratio

Eligibility

Inclusion criteria

Inclusion criteria: a. Clinico-radiologically diagnosed patients of OA knee b. Patients willing to participate and give signed informed consent c. Either gender d. Age >40 years

Exclusion criteria

Exclusion criteria: a. History of peptic ulcer, acid peptic disease or any other concurrent illness b. End organ damage. RFT, LFT will be conducted pre and post session. d. Chronic smoker/ alcoholic e. History of allergy against herbal products or NSAIDs f. Subjects who cannot be relied upon to comply with instructions g. Pregnant or breast feeding women h. Gouty Arthritis, Rheumatoid Arthritis, Psoriatic arthritis.

Design outcomes

Primary

Measure	Time frame
difference between WOMAC score in two groups Timepoint: at baseline after one month after second month	—

Secondary

Measure	Time frame
decrease in level of CTX2 in urine samples of two groups.Timepoint: at baseline and after second month	—

Countries

India

Contacts

Public ContactDrAmol Deshmukh

Pharmanza Herbal Pvt. Ltd.

rd@pharmanzaherbals.com9898652936

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026